Today's News |
Precision NanoSystems to Launch NxGen Blaze and NxGen Blaze+ at the 2019 Controlled Release Society Annual Meeting
Friday, August 2, 2019Company Profile | Follow Company
Vancouver, BC, August 2, 2019--(T-Net)--Precision NanoSystems (PNI), a biotechnology company pioneering innovative solutions for the development of genetic nanomedicines for gene and cell therapy used in oncology, rare disease and infectious disease, announced the official commercial launch of NxGen Blaze and NxGen blaze+ at the 2019 CRS Annual Meeting & Exposition, in Valencia, Spain.
The proprietary NxGen microfluidic mixer platform is designed exclusively for scalable development of nanomedicines from bench to bedside.
The Blaze instrument has been reengineered to integrate the NxGen microfluidic mixer platform. Introducing the NxGen Blaze and the NxGen Blaze + The NxGen Blaze and NxGen Blaze + enable development of nanomedicines faster and for lower cost.
About Precision NanoSystems Inc.
Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com.
Other Recent Company News |
|||||||||||||||||||
|